GLOBE & GUARD Model - Evaluation Contract
Forecast New Requirement Updated
- Agency
-
Centers for Medicare and Medicaid Services
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $10,000,000 to $20,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541720 Research and Development in the Social Sciences and Humanities
- Forecast number
- 270037
- Points of contact
Forecast details come from CMS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Centers for Medicare and Medicaid Services (CMS) plans to issue a competitive IDIQ/GWAC order for a new evaluation contract supporting its proposed GLOBE and GUARD drug pricing models, with solicitation release estimated for March 15, 2027 and award estimated for May 10, 2027. GLOBE (Global Benchmark for Efficient Drug Pricing) would be a proposed mandatory model assessing rebates on certain Medicare Part B drugs whose prices exceed those paid in economically comparable countries, and GUARD (Guarding U.S. Medicare Against Rising Drug Costs) would apply the same approach to certain Part D drugs. The order is placed under the CMS Research, Measurement, Assessment, Design and Analysis (RMADA) 2 IDIQ, falls under NAICS 541720 with PSC AN42, carries no set-aside, and is managed by CMMI's RRCEG under contracting office 7500-7530-00500.
The estimated award value range is $10 million to $20 million, with the current fiscal year value at least $10 million and less than $20 million, and the contract is cost plus fixed fee with a length greater than 5 years beginning May 10, 2027. Points of contact are John Cruse, Contracting Officer (john.cruse1@cms.hhs.gov, +1 (410) 786-7762), and Caroline Ly (caroline.ly@cms.hhs.gov, +1 (410) 786-8114), both at CMS.
Forecast text
GLOBE (Global Benchmark for Efficient Drug Pricing) Model. The Global Benchmark for Efficient Drug Pricing (GLOBE) Model is a proposed mandatory model that would assess a rebate for certain drugs payable under Medicare Part B if the prices exceed those paid in economically comparable countries. GUARD (Guarding U.S. Medicare Against Rising Drug Costs) Model is a proposed mandatory model that would assess rebates for certain drugs payable under Medicare Part D if the prices exceed those paid in economically comparable countries.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast